vs
Oatly Group AB（OTLY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Oatly Group AB的1.7倍（$772.1M vs $456.6M），Revvity净利率更高（12.7% vs -18.5%，领先31.3%），Oatly Group AB同比增速更快（8.1% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-11.3M）
Oatly Group AB是源自瑞典的食品企业，90年代依托隆德大学的研究成果创立，总部设于马尔默，在兰斯克鲁纳拥有研发与生产中心。该公司主打燕麦基乳制品替代产品，其中燕麦乳最为知名，目前在美国证券市场公开上市。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
OTLY vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$456.6M
营收增速更快
OTLY
高出2.3%
5.9%
净利率更高
RVTY
高出31.3%
-18.5%
自由现金流更多
RVTY
多$173.1M
$-11.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $456.6M | $772.1M |
| 净利润 | $-84.6M | $98.4M |
| 毛利率 | 32.2% | — |
| 营业利润率 | -5.9% | 14.5% |
| 净利率 | -18.5% | 12.7% |
| 营收同比 | 8.1% | 5.9% |
| 净利润同比 | 32.8% | 3.9% |
| 每股收益（稀释后） | $-0.14 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OTLYRVTY
| Q4 25 | $456.6M | $772.1M | ||
| Q3 25 | — | $698.9M | ||
| Q2 25 | $208.4M | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | $422.3M | $729.4M | ||
| Q3 24 | — | $684.0M | ||
| Q2 24 | $202.2M | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润OTLYRVTY
| Q4 25 | $-84.6M | $98.4M | ||
| Q3 25 | — | $46.7M | ||
| Q2 25 | $-55.9M | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | $-126.0M | $94.6M | ||
| Q3 24 | — | $94.4M | ||
| Q2 24 | $-30.4M | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率OTLYRVTY
| Q4 25 | 32.2% | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | 32.5% | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | 29.3% | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | 29.2% | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率OTLYRVTY
| Q4 25 | -5.9% | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | -10.6% | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | -28.1% | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | -19.3% | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率OTLYRVTY
| Q4 25 | -18.5% | 12.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | -26.9% | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | -29.8% | 13.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | -15.1% | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）OTLYRVTY
| Q4 25 | $-0.14 | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | $-0.09 | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | $-0.21 | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | $-0.05 | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.3M | $919.9M |
| 总债务越低越好 | $523.0M | — |
| 股东权益账面价值 | $19.7M | $7.3B |
| 总资产 | $787.2M | $12.2B |
| 负债/权益比越低杠杆越低 | 26.59× | — |
8季度趋势，按日历期对齐
现金及短期投资OTLYRVTY
| Q4 25 | $64.3M | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | $67.9M | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $98.9M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | $142.7M | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务OTLYRVTY
| Q4 25 | $523.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $120.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $446.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益OTLYRVTY
| Q4 25 | $19.7M | $7.3B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | $96.7M | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $106.1M | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | $245.8M | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产OTLYRVTY
| Q4 25 | $787.2M | $12.2B | ||
| Q3 25 | — | $12.1B | ||
| Q2 25 | $803.1M | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | $804.0M | $12.4B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | — | $13.4B |
负债/权益比OTLYRVTY
| Q4 25 | 26.59× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-11.3M | $161.8M |
| 自由现金流率自由现金流/营收 | -2.5% | 21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-189.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流OTLYRVTY
| Q4 25 | $-8.7M | $182.0M | ||
| Q3 25 | — | $138.5M | ||
| Q2 25 | $-15.0M | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | $-28.4M | $174.2M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | $-86.0M | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流OTLYRVTY
| Q4 25 | $-11.3M | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | $-24.8M | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | $-47.9M | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | $-105.7M | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率OTLYRVTY
| Q4 25 | -2.5% | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | -11.9% | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | -11.3% | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | -52.3% | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度OTLYRVTY
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 4.7% | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | 4.6% | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | 9.7% | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率OTLYRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OTLY
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
